Bayer HealthCare to present new Stivarga data at ASCO-GI

Bayer HealthCare has announced plans to attend the 2013 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI), where it will present data on its colorectal cancer therapy Stivarga.

During the event in San Francisco, the company will highlight new analyses of the pivotal phase III trial Correct, which assessed the regorafenib-based treatment among metastatic colorectal cancer patients.

Studies will focus on the time course of regorafenib-associated adverse events and mutational analysis of biomarker samples from the trial.

Bayer HealthCare will also be presenting data from a phase I study assessing the potential of the compound as a therapy for hepatocellular carcinoma.

Regorafenib was approved by the US Food and Drug Administration for sale under the Stivarga brand name in September 2012, based on positive results from the Correct trial.

The drug was submitted for regulatory approval in Japan earlier this month for use in the treatment of gastrointestinal stromal tumours.